Set as homepage \ Join in collection
中文

Faculty

Current Location: English Home > Faculty > Department of Epidemiology and Biostatistics > Feng Sun

Feng Sun

Feng Sun

Feng Sun

  • Associate Professor
  • sunfeng@bjmu.edu.cn
  • Xueyuan Road 38, Haidian District, Beijing, China
  • Peking University
Personal profile

Education and Working Experience

Dr. Sun, the deputy director of Peking University Center for Evidence Based Medicine and Clinical Research, received her PhD in Epidemiology and Health Statistics from the School of Public Health, Peking University in 2009 on pharmaco-epidemiology and evidence-based medicine, then she finished the post-doctoral research in Clinical Pharmacy and Pharmaco-epidemiology in School of Pharmacy, Peking University from 2010 to 2012. Afterwards, she worked as Visiting Associate Professor of Department of Population Medicine, Harvard Medical School from 2017 to 2018.


Dr. Sun has led 3 research projects funded by the National Natural Science Foundation of China, 1 research sub-project from National Key R&D Program of China (2021YFC2301601), more than 10 research projects funded by national ministries, and participated more than 20 studies in chronic disease epidemiology, pharmaco-epidemiology and evidence-based medicine. As the chief editor or deputy chief-editor, she undertook the organization and writing of 7 academic books, and published more than 130 articles in Chinese and English as the first or corresponding author. In 2013, Dr. Sun won the title of "Rising Star" of Asia-Pacific Pharmaco-epidemiology Association, and in 2018 won the ATS Foundation MECOR Award, and being the tutor of an outstanding winner project in the Wusi Youth Academic Price in the PKU in 2019. In 2021, she won the Teaching Excellence Award of Peking University Health Science Center and the Teaching Fund of Peking University Zhongwai Medicine. Also, in 2021, she was selected as a key member of the Traditional Chinese Medicine Inheritance and Innovation Team of the State Administration of Traditional Chinese Medicine.


Academic Titles

At present, Dr. Sun is the vice director of the Committee of Specialty Boards of Evidence-Based Medicine in Chinese Medical Doctors’ Association, vice director of the Youth Committee of Clinical Epidemiology and Evidence-Based Medicine Branch of Beijing Medical Association, vice leader of the Youth Committee of Pharmaco-epidemiology of Chinese Pharmaco-epidemiology Society, member of the Standing Committee of China International Exchange and Promotive Association for Medical and Health Care, vice leader of Methodology Group of Evidence-Based Medicine branch of China Preventive Medicine Association, member of the sixth Clinical Toxicology Committee of Chinese Society of Toxicology, member of the Standing Committee of the Compilation Committee of Evidence-Based Medicine Textbooks for colleges and universities in China (academic secretary), expert of Beijing Municipal Commission of Science and Technology in Medical and Health Field, member of the Technical Working Group on National Immunization Program, member of academic Committee of Key Laboratory of Pharmacovigilance Technology Research and Evaluation, National Medical Products Administration.


Dr. Sun is currently the co-director of Cochrane Geographic Group Host Institution of Peking University, and also is the group leader of "advanced methodology of systematic reviews and meta-analysis (AM-SRMA)" in Cochrane China Network. And also, she is the vice director of Clinical Efficacy Evaluation Professional Committee of the World Federation of Chinese Medicine Societies (WFCMS), the member of ISPE and APCE in the field of pharmacoepidemiology.

Dr. Sun is also the editor or corresponding editor of the Chinese Medical Journal (English version), Clinical Trials (Chinese version), Chinese Journal of Epidemiology, the Chinese Journal of Evidence-Based Medicine, Chinese Journal of Evidence-based Cardiovascular Medicine, Chinese Journal of Evidence-based Pediatrics and the journal Pharmacoepidemiology.

Main research directions

Pharmaco-epidemiology; Evidence-Based Medicine; Clinical Epidemiology

Dr. Sun’s interests are in the field of pharmacoepidemiology, evidence-based medicine and Clinical Epidemiology, in particular the use of new methodology to conduct Comparative Effectiveness Research. She has published widely in the areas of cardiovascular, endocrine, cancer and neurodegenerative disease epidemiology and medication safety. Now she is working on several potential new projects for integrating different data resources by building an innovational collaborative model, such as to combine randomized controlled trials, literature data and real-world data from medical platforms around the world.

Representative scientific research projects

1. 2021.01-2024.12. Demonstration and its application on calibrating estimates of real-world treatment effectiveness in patients with type 2 diabetes: Maximizing the applicability of clinical trials. Founded by the National Natural Science Foundation of China (NSFC No. 72074011);

2. 2021.11-2024.12. National Key R&D Program of China Project sub-Project: Appropriate Methods and Real-World Surveillance Strategies for active vaccine Safety Monitoring (No. 2021YFC2301601)

3. 2017.01-2020.12. Developing methodological guidance for evidence-based evaluation of cancer screening programs in the Chinese setting and its application. Founded by the National Natural Science Foundation of China (NSFC, No. 71673003);

4. 2014.01-2016.12. Quality Evaluation of Multiple Treatments Meta-analysis and Study on Several Pivotal Statistical Methods. Founded by the National Natural Science Foundation of China (NSFC, No. 81302508);

5. 2022.03-2028.12. Impact of HPV Vaccination on HPV Infection and Cervical Related Disease Burden in Real-World Settings (HPV-RWS): A Prospective Cohort. (from Company)

6. 2022.01-2022.12. Data analysis and study design of "A real world study on TCM treatment of COVID-19". (from Hospital) 

7. 2021.08-2022.08. The second batch of key projects of China Drug Regulatory Science Action Plan, Entrusted by Drug Evaluation Center of National Medical Products Administration [No.10]: Research on the vigilance technology and methods of drugs and medical devices 

8. 2021.11-2022.12. Chinese Center for Disease Control and Prevention: Literature study on vaccine safety and construction of national Active Vaccine Safety Monitoring Platform 

9. 2021.11-2022.12. Chinese Society of Toxicology clinical Toxicology Specialty (2021) Orientation entrusted project (CST2021CT102): Research on the guiding principles and method validation of multi-source Electronic Diagnosis and Treatment Data Convergence analysis 

10. 2021.08-2022.06. National Cancer Center of China orientation entrusted project: Literature retrieval and systematic review of guidelines for screening and early Diagnosis and early treatment of liver cancer 

11. 2020.08-2021.12. Cancer Hospital of Chinese Academy of Medical Sciences, Entrusted project: Literature retrieval and systematic review of colorectal cancer screening and early diagnosis and early treatment guidelines

12. 2020.11-2021.11. Chinese Society of Toxicology clinical Toxicology Specialty (2020) Orientation entrusted project: Study on the causal inference strategy of constructing the risk cohort of heart failure caused by three novel hypoglycemic drugs based on multi-source and multi-dimensional data 

13. 2021.01-2021.12. Systematic Evaluation of the Online Teaching Effect of Evidence-Based Medicine Course and Empirical Research on Canvas Platform Course. Founded by Education Big Data Research Project of PKU;

14. 2020.07-2022.07. Textbook Composing: Theory and Practice of Network Meta-analysis. Founded by the Peking University Medical Publishing Foundation;

15. 2020.1-2021.12. The Research on the Design and Practice of Mixed Teaching Mode based on Canvas Platform-A case study of Medical Postgraduate in Network Meta-analysis course. Key project of ‘Innovative programs of Teaching 2.0’ of PKU (No. 2020ZD001);

16. 2020.09-2021.07. The Systematic Review and Network Meta-analysis of SGLT2 inhibitors in the Treatment of Type 2 Diabetes. Founded by the Health Science and Technology Promotion Association of Beijing;

17. 2019.11-2020.06. The Clinical Investigational Study on Risks and Influencing Factors of the Ultrasound Gel. Founded by the Adverse Reaction Monitoring Center of Beijing;

18. 2019.08-2020.08. The Research on Statistical Analysis Method of Proactive Monitoring Data. Founded by the Drug Evaluation Center, National Medical Products Administration;

19. 2019.06-2021.05. The Research on the Methods of the Post-marketing Safety Surveillance and Evaluation of Drugs. Founded by the Drug Evaluation Center, National Medical Products Administration;

20. 2018.4-2018.08. Evidence-based evaluation of the benefits of G (M1) Ganglioside. Founded by the Center for Drug Evaluation, National Medical Products Administration;

21. 2018.9-2019.06. Evidence-based evaluation of the safety of Surgical Bioprosthetic Valve. Founded by the Adverse Reaction Monitoring Center of Beijing;

22. 2018.09-2020.12. The Epidemiological Study Design, Database Establishment and Data Statistical Analysis of the Human Toxicity of Metal Ions Release from Artificial Hip Joint. Founded by the Adverse Reaction Monitoring Center of Beijing;

23. 2016.10-2017.06. Evidence-based Evaluation of the Main Adverse Events of Implantable Cardiac Pacemaker. Founded by the Adverse Reaction Monitoring Center of Beijing;

24. 2016.08-2017.08. Research on Inappropriate Medication Use Prescription Detection Model-based on Big Data of National Monitoring System of Irrational Drug Use. Founded by the Peking University Medical Science - Information Science joint research seed fund project (BMU20160581).

25. 2015.08-2016.12. Investigation of the Adverse Events of Liver Injury Induced by Polygonum multiflorum: A Cross-sectional Study. Founded by Center for Drug Evaluation, National Medical Products Administration;

26. 2015.05-2015.12. The Evidence-base Evaluation of the Safety of Artificial Hip Joint. Founded by the Adverse Reaction Monitoring Center of Beijing;       

27. 2014.03-2015.12. The Study on the Post-marketing Risk Surveillance and Evaluation Method of Medical Devices. Founded by the Adverse Reaction Monitoring Center of Beijing;

28. 2013.03-2013.11. The Literature Review and Evaluation of the Tripterygium wilfordii Medicine for Children. Founded by Center for Drug Evaluation, National Medical Products Administration.

29. 2010.01-2013.12. A Cohort Study and Factor Analysis of on the Metabolic Syndrome (MS) on the Prediction of MS and its Main Factors in Type 2 Diabetes Mellitus (T2DM) and Cardiovascular Disease (CVD) in Xinjiang Kazak. Founded by Xinjiang Bingtuan Doctor Foundation.

10 representative papers

1. Sun Feng (Chief Editor), Yang Zhirong, Zeng Xiantao and Zhan Siyan. Interpretation of Medical research reporting guidelines, Beijing, Peking University Medical Press, 2015. (ISNB:978-7-5659-1170-5).

2. Sun Feng (Chief Editor), Zhan Siyan (Chief Reviewer). The Common Statistical Analysis Methods in Clinical Research - An SPSS Example Tutorial. Beijing, Science Press, 2020. (ISNB: 9787030660879)

3. Zhan Siyan (Chief Editor), Wang Congxia, Sun Feng (Associate Editor). Systematic Review and Meta-Analysis, People's Medical Publishing House, 2019 (ISBN: 978-7-117-29045-6)

4. Chen Yaolong (Chief Editor), Sun Feng, Du Liang (Associate Editor). The Application of GRADE in Systematic Evaluation and Practical Guidance. China Union Medical College Press. 2021 (ISBN: 9787567917231)

5. Sun S#, Yang Q#, Zhou Q, Cao W, Yu S, Zhan S, Sun F*. Long-term exposure to air pollution, habitual physical activity and risk of non-alcoholic fatty liver disease: A prospective cohort study. Ecotoxicology and Environmental Safety,2022;235: 113440.

6. Sun S#, Yang Q#, Zhou Q, Cao W, Yu S, Zhan S, Sun F*. Long-term exposure to fine particulate matter and non-alcoholic fatty liver disease: a prospective cohort study. Gut,2022;71(2):443-445.

7. Gao S#, Yang Q#, Wang X, Hu W, Lu Y, Yang K, Jiang Q, Li W, Song H*, Sun F*, Cheng H*. Association Between Drug Treatments and the Incidence of Liver Injury in Hospitalized Patients With COVID-19. Frontiers in Pharmacology, 2022;13:799338.

8. Song H*, Pei X, Liu Z, Shen C, Sun J, Liu Y, Zhou L, Sun F*, Xiao X*. Pharmacovigilance in China: Evolution and future challenges. British Journal of Clinical Pharmacology, 2022: 1-13.

9. S Chai, S Yu, Z Yang, S Wu, L Gao, H Wang, Y Zhang, S Zhan, L Ji*, F Sun*. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Research & Care, 2019;7(1): e000728.

10. S Wu, L Gao, A Cipriani, Y Huang, Z Yang, J Yang, S Yu, Y Zhang, S Chai, Z Zhang, F Sun*, S Zhan*. The effects of incretin-based therapies on β-cell function and insulin resistance in type 2 diabetes: A systematic review and network meta-analysis combining 360 trials. Diabetes, Obesity and Metabolism, 2019;21(4):975-83.

  • Telephone: 010-82801620

  • Fax: 010-82801530

  • Email: pkusph@bjmu.edu.cn

  • School of Public Health